AI assistant
Athira Pharma, Inc. — Director's Dealing 2022
May 27, 2022
35038_dirs_2022-05-27_cf8f8f9a-d0d6-4ad7-9ab0-63ed20e417a2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-05-20
Reporting Person: PERCEPTIVE ADVISORS LLC (Director, 10% Owner)
Reporting Person: PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-05-20 | Stock Option (Right to Buy) | $8.93 | A | 13871 | Acquired | 2032-05-19 | Common Stock (13871) | Indirect |
Footnotes
F1: The shares subject to the option will vest on the earlier of (i) May 28, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022.
F2: Consists of options to purchase shares of the Issuer's common stock awarded to Joseph Edelman in connection with his role as a member of the Issuer's Board of Directors. Mr. Edelman is the managing member of Perceptive Advisors LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset.